# Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission

> **NCT07644481** · NA · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 30 (estimated)

## Conditions studied

- AML (Acute Myelogenous Leukemia)
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient

## Interventions

- **DRUG:** CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen

## Key facts

- **NCT ID:** NCT07644481
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-20
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644481, "Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete Remission". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*